Last week we were glad to attend TERMIS-EU workshop in Nantes, dealing with 3D bioprinting in cancer research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product range, about iPSC-derived hepatocytes in BIOMIMESYS® Liver, and about BIOMIMESYS® for organ-on-chip systems… Moreover, we Read more…
Véronique De Conto, doctorante chez HCS Pharma, présentera ce jeudi 28 mars à Lille, au congrès annuel de la Société Cerveau et Maladies Cérébrovasculaires, le développement d’un modèle cérébral en 3 dimensions incluant le microenvironnement matriciel pour la recherche de nouveaux médicaments contre la maladie de Parkinson. Introduction : 90% Read more…
We are developing a new BIOMIMESYS® hydroscaffold for neuronal cells. First results are very promising because neurons grow and form neurites. Moreover cells lived longer than in monolayer culture. We are currently finalizing this new hydroscaffold to find the best conditions of 3D neuron culture, but BIOMIMESYS® Brain will be soon Read more…
Hepatocytes in primary cultures are still the gold standard in the pharmaceutical industry ; however they are expensive and have a very short lifespan with a progressive loss of specific functions over time. The dipolar aprotic solvent, dimethyl sulfoxide (DMSO) is wildly used to stabilize the liver specific function of Read more…
In HCS Pharma we strongly believe that 3D is the right way to improve drugs dicovery processes. It’s why we develop our 3D hydroscaffold matrix BIOMIMESYS® for 3D cell culture and we invest in 3D pictures acquisition (and analyse) with our partner Molecular Devices. Then we are very please to Read more…
For ethical and cost-related reasons, use of animals for the assessment of mode of action, metabolism and/or toxicity of new drug candidates has been increasingly scrutinized in research and industrial applications. Physiologically based pharmacokinetic (PBPK2) modeling is the most potent in silico tool used for extrapolation of pharmacokinetic parameters to Read more…
BIOMIMESYS® Technology is a biomimetic hydrogel based on biofunctionalized hyaluronic acid with extracellular matrix components
In a study published last October in the journal Stem Cell Research, Chandrasekaran et al. compared the induction of neural progenitor cells (NPCs) from human induced pluripotent stem cells (hiPSCs) obtained by 2D and 3D culture methods. Neural differentiation of five hiPSC lines was analyzed at the protein level by Read more…
culture + acquisition + analyse + visualization … in 3D !
3D to 2D reduction with maximum accuracy
We were in Saint Malo for the first meeting on DYRKs related disease
3D cell models are now attracting a huge interest from scientists working both on toxicity and pharmacology assay development. They are considered more relevant at mimicking the in vivo situation. However, phenotypic assays on these models can be challenging, and are at least more complex.
At HCS Pharma, we work on many of the most exiting medical technologies !
ESTIV conference, named In Vitro Toxicology for Human Safety Assessment, takes place this week in Juan-les-Pins. This congress brings together a lot of toxicologists, from public and private, to discuss the last development of predictive in vitro models in safety testing, as 3D models, organ-on-a-chip, bioprint organs. To learn more and to exchange on these Read more…
We just begin a test period of the Operetta “High Content Imaging System” from Perkin Elmer. First impressions are very goods, especially using confocal option for 3D imaging.
More and more articles show the advantages of #3d culture compared to 2D in #oncology field. This article describe how to do high throughput using 3D culture by rapid size profiling analysis over time on tumor spheroids. “Tumor size is the most frequently used in vivo endpoint when assessing antitumor efficacy in Read more…